TrialAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study.

María Pascual-Lucas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.